Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
Key Highlights
- ➤FINALE trial sites doubled to twelve across the United States
- ➤Baylor Research Institute and Columbia University Medical Center joined the trial network
- ➤FDA-approved protocol requires one-year data from 401 women for approval submission
- ➤FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025
Expert Statements
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc.
“Our August 2026 financing has enabled us to meaningfully advance the FINALE trial, and doubling our investigative sites demonstrates important progress in executing on our U.S. regulatory strategy.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc.
“FemBloc’s approval in Europe marked the beginning of access outside the U.S. and now enables the collection of post-market real-world data.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc.
“Together with evidence from our U.S. pivotal trial, these data will support broader adoption.”
Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc.
“As we work to complete the U.S. study and pursue FDA approval, we are building toward expanded access to this revolutionary option for women globally.”
ATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has doubled the number of actively enrolling sites in its FemBloc(®) FINALE Pivotal Trial to twelve across the United States. The coast-to-coast network of academic centers and private clinical practices now includes Baylor Research Institute and Columbia University Medical Center, joining existing academic sites Maimonides Medical Center, Stanford University, University of California Davis and the University of Utah. Participation by these prominent centers reflects broad clinical interest in advancing permanent birth control options for women through this landmark study and marks continued progress in Femasys’ U.S. clinical program.
Get started
Create a free account to read the full story.